ArticleFrontiers in oncology2026
Predicting treatment-related cardiovascular risks in breast cancer patients: development and validation of an interpretable machine learning model.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to develop and validate an interpretable machine learning model to predict the 1- to 3-year risk of cardiovascular events in breast cancer patients by integrating baseline and treatment variables, while preliminarily investigating the potential association between short-term cardiac function decline and long-term adverse cardiovascular events. Methods: We analyzed electronic medical records from 31,878 breast cancer patients. A composite cardiovascular event outcome was used. Predictors were selected via a two-step process: removing highly correlated variables (|r|≥0.7) and applying LASSO regression with 10-fold cross-validation, which refined 62 initial variables down to 18. Five models were built and compared using the area under the receiver operating characteristic curve (AUC-ROC). The optimal model was interpreted using SHapley Additive exPlanations (SHAP). Results: Among 31,878 breast cancer patients, 3,960 (12.4%) experienced cardiovascular events. The XGBoost model demonstrated the best overall discriminative performance (AUC = 0.790). SHAP analysis identified endocrine therapy, anemia management therapy, and history of cerebrovascular disease as the top three predictors. Crucially, short-term decline in cardiac function was also selected as a significant predictor, supporting its role as a precursor to long-term events. Model robustness was confirmed via sensitivity analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.